©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
C2 Region-derived Peptides Inhibit Translocation and Function of Protein Kinase C in Vivo(*)

(Received for publication, July 9, 1995)

Dorit Ron (§) Jianhua Luo (1) Daria Mochly-Rosen(§)(¶)

From the Department of Molecular Pharmacology, School of Medicine, Stanford University, Stanford, CA 94305-5332 and the Columbia-Presbyterian Cancer Center, Columbia University, New York, New York 10032

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

RACK1 is a protein kinase C (PKC)-binding protein that fulfills the criteria previously established for a receptor for activated C-kinase (RACK). If binding of PKC to RACK anchors the activated enzyme near its protein substrates, then inhibition of this binding should inhibit translocation and function of the enzyme in vivo. Here, we have identified such inhibitors that mimic the RACK1-binding site on betaPKC. We first found that a C2-containing fragment, but not a C1-containing fragment of betaPKC, bound to RACK1 and inhibited subsequent betaPKC binding. The RACK1-binding site was further mapped; peptides betaC2-1 (betaPKC(209-216)), betaC2-2 (betaPKC(186-198)), and betaC2-4 (betaPKC(218-226), but not a number of control peptides, bound to RACK1 and inhibited the C2 fragment binding to RACK1. Peptides betaC2-1, betaC2-2, and betaC2-4 specifically inhibited phorbol ester-induced translocation of the C2-containing isozymes in cardiac myocytes and insulin-induced betaPKC translocation and function in Xenopus oocytes. Therefore, peptides corresponding to amino acids 186-198, and 209-226 within the C2 region of the betaPKC are specific inhibitors for functions mediated by betaPKC.


INTRODUCTION

Protein kinase C (PKC) (^1)isozymes are phosphatidylserine (PS)- and diacylglycerol (DG)-dependent kinases (1) that translocate from the soluble fraction to the cell particulate fraction following activation(2, 3) . Several PKC isozymes are present in each cell type. The isozymes are localized to different subcellular compartments(4, 5, 6) , and following stimulation, each translocates to distinct intracellular structures(7) . The translocation and binding of PKC isozymes to different intracellular structures suggests distinct physiological roles for individual isozymes. We previously demonstrated that inhibition of PKC translocation inhibits its function(8, 9) . Therefore, inhibitors that prevent the translocation of specific isozymes, can provide pharmacological tools to determine the function of each isozyme.

The PKC isozymes can be divided into three subfamilies: conventional cPKC, novel nPKC, and atypical aPKC(10) . Each PKC isozyme contains unique (V) regions. In addition, there are regions common to all the isozymes. The subfamilies differ from each other in the common (C) regions within their regulatory domains. The regulatory domain of the cPKC isozymes contains two common regions, C1 and C2. The C1 region consists of two cysteine-rich loops that mediate DG and phorbol ester binding(11, 12, 13) . C1 is also found in the nPKC subfamily and one of the cysteine loops is found in the aPKC subfamily(14, 15, 16) . The C2 region is present only in the cPKC subfamily and mediates calcium binding; all the C2-containing isozymes require calcium for their activity(10) . This region may also serve as a low affinity calcium sensor(17) . In addition, the C2 region mediates PS binding(18) . However, recent studies indicate that the V1 and C1 regions also mediate calcium and PS binding(19, 20) . Finally, the C2 regions of other C2-containing proteins were proposed to mediate direct binding of these translocating proteins to lipids at the plasma membrane(21) .

Translocation of PKC to the cell particulate fraction was thought to reflect direct binding of the enzyme to lipids at the plasma membrane. However, data from several laboratories including our own indicate that translocated PKC interacts with proteins at the site of translocation (2, 22, 23, 24, 25, 26, 27, 28) . We have identified several proteins from the cell particulate fraction that bind PKC only in the presence of its activators(24) . Binding of PKC to these proteins was concentration dependent, saturable, and specific, suggesting that these binding proteins are receptors for activated C-kinase, or RACKs(24) . Recently, we cloned RACK1, a gene encoding for a 36-kDa homolog of the beta subunit of G proteins (accession number U03390) that fulfills the criteria for RACKs(25) . RACK1 is neither a PKC substrate nor an inhibitor(25) . Rather, it increases PKC phosphorylation of substrates presumably by stabilizing the active form of PKC(25) .

The RACK1-binding site on PKC is unknown. If this site is identified, peptides that mimic the binding site could serve as specific inhibitors of PKC translocation and function. Our previous studies suggested that the C2 region of cPKC contains at least part of the RACK-binding site on the enzyme; other C2-containing proteins such as synaptotagmin (29) and phospholipase C (30) also bind to a mixture of RACKs prepared from the cell particulate fraction. In addition, recombinant fragments of synaptotagmin containing the C2 homologous region bind to RACKs and inhibit PKC binding to RACKs(29) . However, these studies were carried out with heterologous C2-containing fragments from synaptotagmin and a preparation containing a mixture of RACKs. Here, we used recombinant RACK1, recombinant fragments of betaPKC containing the C1 or the C2 regions, and short synthetic peptides derived from the C2 region, to identify the RACK1-binding site on betaPKC. We found that the C2 region contains at least part of the RACK1-binding site on PKC and that some C2-derived peptides act as specific inhibitors of hormone-induced translocation and functions of the C2-containing betaPKC isozymes.


EXPERIMENTAL PROCEDURES

Peptides and Reagents

Peptide betaC2-1 (KQKTKTIK; betaPKC(209-216)), was synthesized at the Biomolecular Resource Center at University of California, San Francisco. betaC2-2 (MDPNGLSDPYVKL; betaPKC(186-198)), scrambled betaC2-1 (TKQKKITK), and control peptide (LQKAGVDG; betaPKC(266-273)) were synthesized at the Protein and Nucleic Acid Facility at Stanford University. betaC2-3 (IPDPKSE; betaPKC(201-207)) and betaC2-4 (SLNPEWNET; betaPKC(218-226)) were a generous gift from Dr. Rafael Nesher, The Hebrew University of Jerusalem, Israel. All the peptides used in this study were over 90% pure. Moreover, most of the peptides were made twice, and each batch gave the same biological activities. 4beta-Phorbol 12-myristate 13-acetate (PMA) was from L. C. Laboratories Inc, and diacylglycerol and phosphatidylserine were purchased from Avanti Inc. PKC was partially purified from rat brain as described previously(31) .

Preparation of RACK1

Recombinant RACK1 was overexpressed in Escherichia coli as a fusion protein with the maltose-binding protein and tagged with a FLAG sequence (DTKDDDDK; Kodak) down-stream from the Xa proteolysis site. The overexpressed protein was then purified on amylose affinity column (Biolabs Inc.). The 36-kDa RACK1 containing the FLAG sequence was recovered after removal of the maltose-binding protein by incubating with factor Xa (5 µg/ml; Biolabs Inc.) for 48 h at 4 °C.

Recombinant Fragments of betaPKC

The plasmids L9 and L10 expressing the C1 (L9) and C2 (L10) regions as fusion proteins with gluthatione S-transferase (GST) were a generous gift from Dr. Bernard Weinstein, Columbia University, New York, and the GST-fusion proteins expressed in E. coli were produced as described(20) .

Overlay Assay

RACK1 was blotted onto nitrocellulose as described elsewhere(24) . Strips of the nitrocellulose sheet (0.5-1 µg RACK1/strip) were incubated in overlay buffer (50 mM Tris-HCl, pH 7.5, containing 0.1% bovine serum albumin, 5 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 0.1% polyethylene glycol, 0.2 M NaCl, 0.1 mM CaCl(2), and 12 mM beta-mercaptoethanol) or preincubated for 30 min at room temperature, in overlay buffer with the indicated peptide (10 µM). L9 or L10 (10 µM) were added in the presence or absence of 50 µg/ml PS, and 1 mM calcium, and the mixture was further incubated for 30 min at room temperature. Where indicated, immobilized RACK1 was first incubated with C2-derived peptides in the absence of PKC activators. PKC fragments in the presence or absence of PKC activators were then added, unbound material was removed, and the strips were washed three times for 5 min with overlay wash buffer (0.1% polyethylene glycol, 0.2 M NaCl, 0.1 mM CaCl(2), 12 mM beta-mercaptoethanol, and 50 mM Tris-HCl, pH 7.5). Binding of fragments L9 and L10 to RACK1 was detected with anti-GST polyclonal antibodies (1:5000, a gift from Dr. Richard Scheller, Stanford University). The strips were then incubated with anti-rabbit horseradish peroxidase-linked antibodies diluted 1:1000 (Amersham Life Science) followed by chemiluminescent reaction. Quantitation of L9 and L10 binding was carried out by analyzing autoradiograms using a Microscan 1000 gel analyzer (Galai Inc., Israel) at linear range of detection.

Column Assay

An amylose suspension (0.5 ml; Biolabs Inc.) was loaded onto a poly-prep chromatography column (Bio-Rad) and washed with column wash buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM EDTA, 1 mM sodium azide, and 10 mM beta-mercaptoethanol). Crude extracts of RACK1-maltose-binding protein fusion protein (1 ml, 10 µg/ml) were loaded and the column washed extensively (20 column volumes). L9, L10 (10 µM), or partially purified rat brain PKC (containing a mixture of PKC isozymes; 10 nM; 200 units/mg) were then added, in the presence or absence of 50 µg/ml PS and 1 mM calcium or 50 µg/ml PS, 0.8 µg/ml DG, and 1 mM calcium in overlay buffer. After incubation while shaking for 30 min at room temperature, unbound material was removed, the column was washed with column wash buffer (20 column volumes), the proteins were eluted with 10 mM maltose in column wash buffer, and the amount of bound betaPKC and L10 determined by Western blot analysis. To this end SDS-PAGE sample buffer (0.3 M Tris-HCl, 5% SDS, 50% glycerol, 0.01% bromphenol blue, and 5% beta-mercaptoethanol) was added, the samples were boiled for 10 min, and loaded on 10% SDS-PAGE gel. Western blot analysis with anti-FLAG antibodies (Kodak; 1:10,000) demonstrated that equal amounts of RACK1 were eluted from all columns by amylose. PKC and L10 levels were then determined using anti-betaPKC monoclonal antibodies (Seikaguku America, Inc; 1:1000). L9 and L10 binding were also detected with anti-GST antibodies, followed by a chemiluminescent reaction as described above.

RACK1 Binding to the C2-derived Peptides

Peptides (1 nmol/slot) were blotted onto nitrocellulose paper using a slot-blot apparatus (Schleicher & Schuell). Unbound material was removed, and the nitrocellulose was incubated for 2 h in overlay block (20 mM Tris-HCl, pH 7.5, 3% bovine serum albumin, 0.1% PEG, 0.2 M NaCl). RACK1 (20 nM) was added in overlay buffer, and the blot was incubated for 30 min at room temperature. Binding of RACK1 to these peptides was determined as described above with anti-FLAG monoclonal antibodies (1:10,000). Binding was quantitated using a MicroScan 1000 Gel Analyzer (Galai Inc. Israel)

Cell Culture

Primary cultures of 90% pure cardiac myocytes were prepared from hearts of 1-day-old rats by gentle trypsinization at room temperature as described(7) . Cells were cultured for 4 days in Lab-Tek chamber slides (Nunc Inc.), pre-coated with laminin (1 µg/ml), in the presence of Dulbecco's modified Eagle's medium, with 5% fetal bovine serum. The culture medium was then replaced with serum-free medium containing transferrin (10 µg/ml) and insulin (5 µg/ml) for 2 days. Bromodeoxyuridine (0.1 mM) was used through the third day of culture to keep the level fibroblasts at 10% or lower(7) .

Permeabilization of Cardiac Myocytes and PKC Translocation: Immunofluorescence Studies

The cells were washed once with PBS and treated with cold permeabilization solution (10 mM EGTA, 140 mM KCl, 20 mM HEPES, 50 µg/ml saponin, 5 mM sodium azide, and 5 mM potassium dioxalate, pH 7.4) together with the indicated peptide (10 µM) for 10 min at room temperature. Permeabilization does not affect the viability of the cells nor does it alter the rate of spontaneous and stimulated contraction, basal or hormone-induced expression of c-fos, and stimulation-induced hypertrophy, indicating that complex cell functions are not altered by the permeabilization. (^2)

PMA-induced translocation of PKC isozymes was determined by immunofluorescence studies as described before(32) . The cells were then washed with PBS, fixed with cold acetone for 3 min, and washed twice with cold PBS. The cells were incubated for 1 h with 1% normal goat serum in PBS containing 0.1% Triton X-100 followed by overnight incubation with anti-betaI, betaII, or PKC polyclonal antibodies (Research and Diagnostic Antibodies; 1:100), anti-PKC polyclonal antibodies (Santa Cruz Biotechnology; 1:100), or anti-RACK1 (Transduction Laboratories; 1;100) diluted in PBS containing 0.1% Triton X-100 and 2 mg/ml bovine serum albumin. The cells were washed three times with PBS containing 0.1% Triton, incubated for 2 h with fluorescein-conjugated anti-rabbit IgG antibodies (to detect binding of anti-PKC antibodies; Organon Teknika; 1:1000) or anti-mouse IgM antibodies (to detect binding of anti-RACK1 antibodies; Boehringer Mannheim; 1:1000) and washed again three times with PBS containing 0.1% Triton. After mounting with Miowiol 4-88 (Calbiochem), the slides were viewed with a Zeiss IM35 microscope using a 40X water immersion objective. Multiple fields of cells for each treatment group and each PKC isozyme were monitored, and the number of cells showing the localization of activated isozyme (32) was recorded. Data are presented as the percentage of cells having the tested isozyme at the activated site. Images of RACK1 and PKC localization from the Zeiss microscope were recorded on Kodak TMax 400 film, and the exposure time was 30 s for these micrographs.

Xenopus Oocyte Maturation Assay

Microinjection of Xenopus oocytes was carried out by Wu and associates (Berkeley, CA) as described previously(8) . Oocytes were injected with 50 nl of the indicated peptide 1 h before insulin treatment (8.25 µg/ml). Insulin-induced oocyte maturation was then determined by monitoring the appearance of a white spot in the animal pole of the oocyte that is indicative of germinal vesicle breakdown and maturation. Ten to 15 oocytes were included in each treatment, and oocytes were scored for up to 35 h after insulin treatment.

Analysis of betaPKC Distribution in Xenopus Oocytes

One hour after microinjection of the indicated peptide to the oocytes (100 oocytes/group), the oocytes were incubated for an additional hour with or without insulin and then homogenates were prepared as described(8) . Samples were diluted in homogenization buffer (500 µl; 20 mM Tris-HCl, pH 7.5, 10 mM EGTA, 20 mM EDTA, 0.25 M sucrose, and 20 µg/ml of each soybean trypsin inhibitor, leupeptin, and aprotonin), and centrifuged at 100,000 times g for 30 min at 4 °C. The supernatant (cytosolic fraction) was removed, and the pellet (particulate fraction) was dissolved in homogenization buffer (500 µl). After addition of sample buffer, these samples were loaded onto 10% SDS-PAGE, and the amounts of betaPKC in both fractions were determined by Western blot analysis using anti-betaPKC antibodies (Seikaguku America 1:1000) followed by IgG rabbit anti-mouse (Zymed Inc. 1:2000) and I-labeled protein A.


RESULTS

Previous studies suggested that at least part of the RACK-binding site on betaPKC lies within the C2-region of the enzyme(29) . In addition these studies suggested that the activators of PKC (PS, DG, and calcium) are required to expose the RACK-binding site on betaPKC rather than for the interaction of the C2 region with RACKs(29) . If the RACK1-binding site on betaPKC is within the C2 region, a C2-containing fragment of betaPKC should bind to RACK1 in a PS-, DG-, and calcium-independent manner. We used two fragments of betaPKC expressed as fusion proteins with GST. One of the fragments, L9, includes the V1 region, the pseudosubstrate sequence, and the C1 and V2 regions (amino acids 3-182)(20) . The second fragment, L10, includes the V1 region, the pseudosubstrate sequence, and the first cysteine repeat from the C1 region, as well as the entire C2 and V3 regions (amino acids 3-76 and 143-339)(20) . In an overlay assay, L10, the C2-containing fragment, but not L9, the C1-containing fragment, bound to RACK1 (Fig. 1). Saturation of binding of L10 to RACK1 was obtained at 1 µM. In contrast, the binding of L9 to RACK1 (Fig. 1, lanes 2 and 4) was minimal, not saturable and similar to the nonspecific binding of GST carrier protein alone (not shown). The V1 region, the pseudosubstrate site, and the first cysteine-loop of C1 are present in both L10 and L9. However, L10 also contains the C2 and V3 regions of PKC. Therefore, these results suggest that the C2 and/or the V3 regions bound to RACK1. In addition, PKC activators PS and calcium did not increase the binding of L10 to RACK1 (Fig. 1, lanes 1versus3). Because these activators are required for the binding of intact PKC to RACK1(25) , the data are consistent with our previous studies (29) suggesting that the PKC activators are required only to expose the RACK-binding site in the intact PKC and that this site is already exposed in the C2-containing fragment L10.


Figure 1: Binding of betaPKC fragments L9 and L10 to RACK1, and effects of calcium and phosphatidylserine. L10 (lanes 1 and 3) and L9 (lanes 2 and 4) (10 µM) were incubated with nitrocellulose blots of SDS-PAGE loaded with RACK1 (0.5 µg-1 µg RACK1/strip) in an overlay assay in the presence (lanes 1 and 2) and absence (lanes 3 and 4) of phosphatidylserine and calcium (PS/Ca). After washing, binding of the fragments was detected with anti-GST antibodies (1:5,000). An autoradiograph, representative of three independent experiments is shown. The arrow indicates the position of RACK1, and the intensity of the bands are proportional to the amount of L9 or L10 bound to RACK1.



If the RACK1-binding site is within the C2 and/or V3 regions of betaPKC, then L10 (which contains these regions) should inhibit the binding of intact betaPKC to RACK1. RACK1 was immobilized on an amylose column, and betaPKC binding in the presence of PS and calcium and L10 or L9 was determined (Fig. 2). In the presence of L10 (Fig. 2, lanes 2versus1), but not L9 (Fig. 2, lane 3), betaPKC binding to RACK1 was completely inhibited. Similar results were also obtained when the effect of the fragments on betaPKC binding to RACK1 was determined using the overlay assay (not shown). Since L10 inhibited betaPKC binding to RACK1, the C2 region and/or the V3 regions, present in L10 and not in L9, are likely to contain at least part of the RACK1-binding site on betaPKC.


Figure 2: betaPKC binding to RACK1 in the presence of L9 and L10. PKC (10 nM) together with L10 (10 µM, lane 2), L9 (10 µM, lane 3), or buffer (lane 1) was incubated with RACK1-maltose binding fusion protein in the presence of phosphatidylserine and calcium for 30 min at room temperature, as described under ``Experimental Procedures.'' After extensive washing, the proteins were eluted from the column with maltose and applied to SDS-PAGE. betaPKC levels were then detected by Western blot analysis with anti-betaPKC antibodies. (This antibody also recognizes fragment L10, but not L9.) The autoradiograph is representative of three independent experiments.



We found that synaptotagmin fragments that contain the C2 homologous region bind to purified RACKs (29) and to recombinant RACK1 (n = 3, data not shown) and inhibit PKC binding to RACKs (29) . We have therefore reasoned that homologous sequences within the C2 region of betaPKC and synaptotagmin may mediate their binding to RACK1. Three betaPKC-derived peptides derived from the homologous sequences of betaPKC and synaptotagmin were prepared (Fig. 3A): betaC2-1 (KQKTKTIK) (betaPKC(209-216), betaC2-2 (MDPNGLSDPYVKL) (betaPKC(186-198), and betaC2-4 (SLNPEWNET) (betaPKC(218-226). In addition, another C2-derived peptide, betaC2-3 (IPDPKSE) (betaPKC(201-207), that shares no homology with synaptotagmin (Fig. 3A), was also synthesized. As seen in Fig. 3B, immobilized peptides betaC2-1, betaC2-2, and betaC2-4, but not betaC2-3, bound directly to RACK1. Similar binding of these peptides to RACK1 in the absence of PKC activators was observed (not shown). An additional control peptide corresponding to betaPKC (amino acids 266-273 in the C2 domain) did not bind to RACK1 (data not shown; n = 3).


Figure 3: A, amino acid alignment of homologous sequences within the C2-region of betaPKC and synaptotagmin (p65). Alignment of part of the C2 region was carried out according to Clark et al.(21) . Boxed areas are the peptides betaC2-1, betaC2-2, betaC2-3, and betaC2-4. Capital letters denote conserved amino acids; lowercase letters denote unique sequences; and -`` denotes a gap. Numbers on the right are the position of the carboxy amino acid in the protein. The percent homology for synaptotagmin and betaPKC in the area indicated is 67%. B, selective RACK1 binding of the C2-derived peptides. The C2-derived peptides betaC2-1, betaC2-2, betaC2-3, and betaC2-4 (1 nmol/slot) were immobilized on nitrocellulose using a slot-blot apparatus, and the immobilized peptides were overlaid with RACK1 (20 nM). Bound RACK1 was detected using anti-Flag antibodies (1:10,000). Shown are average results of four independent experiments for betaC2-1 and betaC2-2 and two independent experiments for betaC2-3 and betaC2-4. C, selective inhibition of L10 binding to RACK1 by the C2-derived peptides. The peptides (10 µM) were incubated with immobilized RACK1 as described under ''Experimental Procedures`` and subsequent binding of L10 to RACK1 determined in an overlay assay. Binding is expressed as percent of that obtained in the absence of peptide and is representative of two independent experiments



If the betaC2-1, betaC2-2, and betaC2-4 peptides represent the binding site for RACK1 in the C2 region, these peptides should inhibit C2 binding to RACK1. As expected, using the overlay assay, we found that when RACK1 was preincubated with betaC2-1, betaC2-2, and betaC2-4 subsequent binding of L10 to RACK1 was inhibited (Fig. 3C). However, minimal or no inhibition of this binding occurred by incubation with betaC2-3 or scrambled betaC2-1 (Fig. 3C). Therefore, amino acids 186-198 and 209-226 of betaPKC appear to be at least part of the RACK1-binding site in the C2 region.

Using primary rat neonatal cardiac myocytes in culture, we have previously demonstrated that activation of PKC by PMA or by norepinephrine causes isozyme-specific translocation to distinct subcellular sites(7, 32) . If these C2-derived peptides mimic the RACK1-binding site on the C2-containing isozymes, they should inhibit stimulation-induced translocation and binding of these isozymes to their RACKs, but not the translocation of the C2-less isozymes. To test this prediction, we first determined whether RACK1 is present in cardiac myocytes. Using anti-RACK1 antibodies, we found RACK1 immunostaining at perinuclear structures and diffusely in the cytosol (Fig. 4A). RACK1 location was not altered by PMA or norepinephrine (3-100 nM and 2 µM, respectively; not shown). However, following activation with norepinephrine or PMA, betaIIPKC immunoreactivity translocated and was co-localized with RACK1 (Fig. 4, A and B, respectively, and not shown). Partial co-localization of activated betaIPKC with RACK1 was also noted (not shown, see also (32) ). In contrast, RACK1 immunoreactivity did not co-localize with inactive or activated C2-less isozymes, or PKC (see in the following and (32) ), suggesting that RACK1 may be a specific anchoring protein for activated betaPKC in cardiac myocytes.


Figure 4: RACK1 and betaIIPKC are co-localized in cardiac myocytes treated with norepinephrine. Cells were treated with 2 µM norepinephrine for 5 min and stained with anti-RACK1 antibodies (A) or anti-betaIIPKC antibodies (B) as described under ''Experimental Procedures.`` Strong perinuclear staining and diffuse cytosolic staining is observed with the two antibodies. Preabsorption of anti-RACK1 with recombinant RACK1 abolishes this immunostaining (not shown). Controls for anti-betaIIPKC antibodies were carried out as described elsewhere (32) .



We next determined whether the C2-derived peptides, that inhibit betaPKC binding to RACK1 in vitro, inhibit activation-induced translocation of these C2-containing isozymes. The peptides were introduced into the cells by transient permeabilization with saponin (50 µg/ml), which has been successfully used to introduce various peptides and other compounds into different cell types(33, 34, 35) . As was demonstrated in cardiac myocytes^2 and other cells(33, 36, 37, 38) , permeabilization with saponin does not affect the viability of the cells nor other cellular functions including contraction rate, gene expression, and cell growth. After permeabilization, the subcellular localization of different PKC isozymes following stimulation with PMA was determined by immunofluoresence as described previously(32) .

Transient permeabilization of these cells in the absence of any peptide did not affect the localization of betaI, betaII, , or PKC isozymes before or after stimulation. betaIPKC in non-stimulated cells was found on cytosolic structures. After exposure to 100 nM PMA for 15 min, antibodies against this isozyme showed localization to perinuclear and intranuclear structures in 80% of the cells (Fig. 5, vehicle). betaIIPKC was also cytosolic before stimulation, and in 80% of the cells it translocated to perinuclear structures after PMA treatment (Fig. 5, vehicle). In contrast, permeabilization in the presence of peptides betaC2-1, betaC2-2, or betaC2-4 (10 µM extracellular concentration) resulted in inhibition of the PMA-stimulated translocation of the betaI and betaIIPKC isozymes by 65-95%, with betaC2-4 causing the largest inhibition (Fig. 5). Other peptides, including scrambled betaC2-1, a control peptide derived from the C2-region outside the synaptotagmin-C2 homology region (betaPKC(266-272)), and the C2-derived peptide betaC2-3 that did not inhibit L10 binding to RACK1 (Fig. 3C) did not affect PMA-induced translocation of betaI and betaIIPKC in cardiac myocytes (Fig. 5).


Figure 5: PMA-induced subcellular distribution of PKC isozymes in neonatal cardiac myocytes. Cardiac myocytes were permeabilized in the presence or absence of peptides (10 µM). After removal of the permeabilization buffer, PMA (100 nM) was added for 15 min, and the cells were fixed with acetone as described under ''Experimental Procedures.`` The subcellular localization of PKC isozymes was then determined with anti-betaI, betaII, and PKC polyclonal antibodies (Research and Diagnostic Antibodies; 1:100), and anti-PKC polyclonal antibodies (Santa Cruz Biotechnology; 1:100). Results are expressed as percentage of cells out of all scored cells with PKC isozyme localized at the activated site (intranuclear for betaIPKC, perinuclear for betaIIPKC, perinuclear and fibrillar for PKC, and on cross-striated structures for PKC(32) ). For each condition, 100-150 cells were scored. Results for the subcellular localization of betaI, betaII, and PKC are mean ± S.E. of seven independent experiments for betaC2-1, eight for betaC2-2, three for betaC2-3, two for betaC2-4, five for betaC2-1 scrambled, and two for the control peptide (betaPKC(266-273)). Results for the subcellular localization of PKC are representative of two independent experiments.



Because the C2 region is present in betaPKC, but not in or PKC, for example(1, 16) , the C2-derived peptides should only affect the translocation of the C2-containing isozymes, but not that of the C2-less isozymes. Similar to non-permeabilized cells, we found that treatment with 100 nM PMA resulted in the translocation of PKC from the nucleus to cross-striated structures in 80% of the cells, whereas PKC translocated from the nucleus to perinuclear and fibrillar cytosolic structures in 90% of the cells. Moreover, as predicted, the translocation of these C2-less isozymes was not affected by introduction of any of the C2-derived peptides into the cells (Fig. 5). These results indicate that the betaC2-1, betaC2-2, and betaC2-4 peptides are specific inhibitors of translocation for the C2-containing cPKC isozymes such as betaI and betaIIPKC, but not for the C2-less nPKC isozymes such as and PKC.

If translocation of betaPKC is required for its function, peptides that inhibit betaPKC translocation should also inhibit betaPKC-mediated function. The function of betaPKC in cardiac myocytes has not yet been determined. Therefore, we used another assay system, insulin-induced maturation of Xenopus oocytes. We previously demonstrated that oocyte maturation is mediated in part by betaPKC; insulin treatment results in translocation of betaPKC (but not other PKC isozymes) from the cytosol to the cell particulate fraction (9) and maturation is delayed by the PKC-specific inhibitor pseudosubstrate peptide(8, 9) . Furthermore, this insulin-induced response is also inhibited when PKC translocation is blocked by injection of purified RACKs (8) or a peptide corresponding to the PKC-binding site on RACKs(9) . Therefore, inhibition of translocation inhibits PKC-mediated function.

If C2-containing isozymes regulate oocyte maturation, microinjection of C2-derived peptides that inhibit the translocation of C2-containing isozymes should delay insulin-induced oocyte maturation. The C2-derived peptides were microinjected into intact oocytes. betaC2-1, betaC2-2, and betaC2-4 (5 µM-500 µM) significantly delayed oocyte maturation in a dose-dependent manner (Fig. 6, A and B, and not shown). When 50% of the vehicle-injected oocytes reached maturation only 3-8% of the oocytes injected with betaC2-1, betaC2-2 and betaC2-4 have responded (Fig. 6C). In contrast, microinjection of betaC2-3 (Fig. 6, B and C), or a number of other control peptides including scrambled betaC2-1 (Fig. 6C), did not affect insulin-induced oocyte maturation (see also (8) ). Therefore, betaC2-1, betaC2-2, and betaC2-4 peptides derived from the RACK1-binding site on betaPKC specifically inhibited insulin-induced regulation of oocyte maturation.


Figure 6: Xenopus oocyte maturation after microinjection of the C2-derived peptides. Time course of insulin-induced Xenopus oocyte maturation at the indicated times after microinjection of vehicle (control, 20 mM NaCl) (), betaC2-1 (box), betaC2-2 (circle) (50 µM). Xenopus oocyte maturation at the indicated time after microinjection of vehicle (control, 20 mM NaCl) (), betaC2-3 (up triangle) and betaC2-4 (bullet) (50 µM). In each experiment, 10-15 oocytes were microinjected. Results are expressed as percentage of oocytes that reached germinal vesicle breakdown and are representative of at least three independent experiments. Percentage of oocytes reaching maturation after microinjection of tested peptides at a time that 50% of vehicle-injected oocytes reached maturation (indicated by a dashed line in A and B). Results are expressed as average ± S.E. and n denotes the number of independent experiments.



We then determined whether this inhibition of PKC function in oocytes was due to prevention of insulin-induced betaPKC translocation to the cell particulate fraction. Since immunofluorescence studies in Xenopus oocytes are not possible, we determined betaPKC translocation by cell fractionation. The distribution of betaPKC between the soluble and particulate fractions of oocytes (100,000 times g supernatant and pellet, respectively) was determined in oocytes injected with vehicle or betaC2-1 using anti-betaPKC antibodies (Fig. 7). Microinjection of betaC2-1 to non-stimulated oocytes did not affect betaPKC distribution (not shown) and was similar to control non-stimulated oocytes (Fig. 7, lanes 1 and 2). In vehicle-injected oocytes, insulin treatment resulted in a decrease in the level of the 80-kDa betaPKC from the cytosol and a corresponding increase in the particulate fraction level (Fig. 7, lanes 4 and 3versus2 and 1). However, no insulin-induced translocation of betaPKC was observed following microinjection of betaC2-1; rather, there was a decrease in the betaPKC level in the particulate fraction (Fig. 7, lanes 5versus1), suggesting degradation of betaPKC. Similar results were also observed following microinjection of betaC2-2 (not shown). Therefore, betaC2-1 and betaC2-2-inhibition of PKC-mediated function following insulin-induced stimulation appears to be due to inhibition of betaPKC translocation.


Figure 7: Effect of betaC2-1 microinjection on the subcellular distribution of betaPKC in Xenopus oocytes. Oocytes were microinjected with vehicle (20 mM NaCl) (lanes 1-4) or betaC2-1 (50 µM; lanes 5 and 6) and the distribution of betaPKC in the particulate (p) and cytosolic (c) fractions was determined 60 min after incubation without (lanes 1 and 2) or with insulin (lanes 3-6). The cell particulate fraction (lanes 1, 3, and 5) and cytosolic fractions (lanes 2, 4, and 6) of the oocytes were prepared as described under ''Experimental Procedures,`` using 100 oocytes for each treatment and PKC was detected using anti-betaPKC antibodies (1:1000) in Western blot analysis. The antibodies reacted with an 80-kDa protein that corresponds with betaPKC. The identity of the two other immunoreactive bands in the particulate fraction of control and insulin-treated oocytes is unknown. (This antibody recognizes both betaI and betaIIPKC isozymes. However, only betaIIPKC appears to translocate on insulin treatment in these cells). The figure is a representative of results obtained in three independent experiments.




DISCUSSION

Using the L9 and L10 recombinant fragments of betaPKC and short peptides derived from the C2 region, we have mapped at least part of the RACK1-binding site on betaPKC to amino acids 186-198 and 209-226 within the C2 region. Furthermore, peptides corresponding to these sequences inhibited the translocation of C2-containing isozymes but not the translocation of C2-less isozymes in neonatal cardiac myocytes. Finally, these peptides inhibited PKC-mediated function in Xenopus oocytes. Since RACK1 immunoreactivity was found in cardiac myocytes (Fig. 4A) and Xenopus oocytes, (^3)it appears likely that the C2-derived peptides inhibited PKC function by binding to RACK1 and blocking subsequent binding of the intact enzyme.

The betaPKC fragment L10 also contains the V3 region of the enzyme, and therefore, our study cannot rule out a role for V3 in binding of betaPKC to RACK1. Since each of the C2-containing isozymes in cardiac myocytes are localized to a different subcellular site(39) , it is likely that isozyme unique sequences (e.g. V1, V3, and V5) also contain isozyme-specific RACK-binding sites in addition to the site within the common C2 region. Other studies suggested that binding of PKC to proteins different from RACK1 is mediated by the pseudosubstrate sequence (via a phospholipid bridge(40) ) or by the catalytic domain of PKC(41, 42) . However, the role of the interaction of PKC with these PKC-binding proteins in vivo has not yet been determined.

Very recently, the role of the C1 region in localizing PKC to the Golgi apparatus has been reported(43) . Golgi functions were inhibited by overexpression of both intact PKC and the C1 fragment of PKC, leading the authors to suggest that the C1 region may mediate subcellular localization. Our studies with the C1 fragment of betaPKC cannot exclude the possibility that this domain may also participate in localizing the enzyme. However, the combined in vitro and in vivo studies indicate that the C2 domain is required for this interaction; inhibitors of the C2 domain binding to RACK1 prevent betaPKC translocation and function.

The C2 region of other translocating enzymes also appears to be required for their translocation and function. Recent data indicate that the C2 region of cytosolic phospholipase A2 associates with membranes, whereas a mutant of this lipase lacking the C2 region does not(44) . In addition, a fusion protein containing 43 amino acids from the C2 region of Ras GTPase (GAP) confers calcium-dependent interaction with cellular membranes, whereas a GAP mutant lacking this region does not(45) . Finally, the binding of synaptotagmin to membranes is abolished by protease treatment of the membrane(46) , and peptides derived from the C2 region of synaptotagmin inhibited calcium-induced neurotransmitter release from the giant squid axon (47) . Therefore, the C2 region appears to mediate translocation for a number of translocating proteins.

It appears that the inhibitory effects of the C2-derived peptides presented here are due to the inhibition of translocation of PKC rather than of other C2-containing translocating proteins. PMA is not thought to induce translocation of phospholipase C or GTPase activating protein, and synaptotagmin immunoreactivity was not found in cardiac myocytes (not shown). Similarly, insulin treatment does not induce translocation of phospholipase C or GTPase activating protein in Xenopus oocytes, nor is there synaptotagmin immunoreactivity in oocytes (data not shown). In addition, progesterone-induced oocyte maturation that does not involve PKC activation (8, 48) was not affected by the C2-derived peptides (n = 3, data not shown). Therefore, the effects of the betaC2-1, betaC2-2, and betaC2-4 peptides are most likely specific for PKC. Because we do not have antibodies that distinguish between betaI and betaIIPKC for Western blot analysis, we could not determine whether one or both mediate the insulin-induced effect.

The inhibitory effects of the betaC2 peptides were sequence-specific. betaC2-1, betaC2-2, and betaC2-4, but not betaC2-3 or a number of control peptides, inhibited translocation of betaPKC. Since betaC2-1 is highly basic (Fig. 3A), it was previously proposed to mediate direct binding of the C2-containing proteins to the negatively charged PS in the membrane(21) . However, we found that its inhibitory activity cannot be attributed to charge only, since a scrambled betaC2-1 peptide was inactive in inhibiting either the translocation of C2-containing betaPKC isozymes (Fig. 5) or their function (Fig. 6).

Why was there a decrease in the levels of betaPKC in activated oocytes injected with peptides betaC2-1 or betaC2-2? Activated PKC has been previously demonstrated to be more sensitive to proteolysis (49) and subsequent inactivation, and we found that co-incubation with RACKs in vitro partially protects from this inactivation. (^4)Since the levels of betaPKC in the absence of insulin treatment did not decrease following microinjection of betaC2-1 and betaC2-2 peptides (not shown), the data are consistent with increased sensitivity of activated betaPKC to proteolysis in the presence of these translocation inhibitors in vivo. Taken together, the data suggest that betaC2-1, betaC2-2, and betaC2-4 bound to the betaPKC-specific RACK in Xenopus oocytes and inhibited betaPKC translocation and function.

Relatively high concentrations (50 µM) of the C2-derived peptides were required to produce inhibition of insulin-induced oocyte maturation. This may be due to degradation of the peptides in the oocytes during the course of the experiments (hours), the effect of the yolk on the distribution of the peptide in the oocytes, and/or because of competition of the endogenous intact PKC for binding to RACKs. In cardiac myocytes, the intracellular concentration of the peptides has not been determined directly. However, using a tracer radioactive probe, the final concentration of the peptide was estimated to be 1 µM when the applied concentration of the peptide is 10 µM.^2 Furthermore, since the peptides are likely to be sensitive to proteolysis, the intracellular concentration in cardiac myocytes is likely to be much lower.

Because the C2-derived peptides specifically inhibited translocation and function of betaPKC in vivo, they belong to a new class of PKC inhibitors, translocation inhibitors. This term was introduced to describe an inhibitor of 5-lipoxygenase, MK0866. MK0866 inhibits the binding of 5-lipoxygenase to its intracellular receptor, FLAP, a binding that is required for activation of the enzyme(50) . We have recently identified additional translocation inhibitors for PKC; a 15 amino acid peptide (peptide I) from other PKC-binding proteins inhibited the interaction between PKC and RACK1 and the function of betaPKC in vivo(9, 51) . Therefore, peptides that mimic the interaction sites on either PKC or RACK are inhibitors of PKC-mediated function.

How do short peptides from the C2 region of betaPKC inhibit PKC translocation and function? Many small ligands are thought to interact with their receptor or enzyme via a ``greasy pocket.'' In contrast, the interaction of two proteins in the cell may reflect multiple binding sites on relatively large surface areas of these proteins. Peptides derived from the interacting areas are likely to have lower affinity for their binding sites as compared to the intact proteins. Yet, if these peptides act as a wedge between the two interacting proteins, they may serve as specific and effective inhibitors.

The structure of the C2 domain of p65 has recently been determined (52) . Examination of that structure demonstrates that betaC2-1, betaC2-2, and betaC2-4 but not betaC2-3 are localized on adjacent exposed regions in the C2 domain. Two of the biologically active peptides (betaC2-1 and betaC2-2) correspond to sequences that contain both loops and beta strand structures. In contrast, betaC2-4, the peptide with the highest biological activity (Fig. 5), corresponds to sequences from only a surface beta strand structure (the fifth beta strand(52) ). It is possible that the interaction surfaces between PKC and RACK1 are constituted only by beta strands. Future experiments utilizing shorter peptides will address this possibility. It is interesting to note that the co-crystal structure of the Ras-binding domain of c-Raf-1 with the small GTP-binding protein Rap1A suggests that the interaction between the two proteins is mediated by single anti-parallel beta strands at the edge of the molecules(53) . The authors also predicted that such a small interaction site between the two proteins provides an opportunity to design drugs that inhibit this interaction. Indeed, our data on betaPKC and RACK1 interaction demonstrate that such inhibitors have the predicted biological activity.

Finally, PKC translocation inhibitors can be used to elucidate the cellular role of specific PKC isozymes. Our finding that the betaC2-1, betaC2-2, and betaC2-4 peptides caused a delay in insulin-induced oocyte maturation indicates that C2-containing isozymes, most likely betaPKC, mediate this function in oocyte maturation. Since in cardiac myocytes, inhibition of translocation of C2-less isozymes was not observed, the inhibitory peptides can be used as tools to identify the PKC isozymes that mediate specific cellular functions in cells in which multiple isozymes are activated by a single stimulus. The role of C2-containing isozymes in the PMA-induced regulation of cardiac myocyte function is currently under investigation using these peptides.


FOOTNOTES

*
This research was supported by Grant HL43380 from the National Institutes of Health (to D. M. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 415-725-7720; Fax: 415-725-2952.

(^1)
The abbreviations used are: PKC, protein kinase C; PS, phosphatidylserine; DG, diacylglycerol; RACK, receptors for activated protein kinase C; PMA, 4beta-phorbol 12-myristate 13-acetate; GST, glutathione S-transferase; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis.

(^2)
J. A. Johnson, M. O. Gray, and D. Mochly-Rosen, manuscript in preparation.

(^3)
D. Ron and D. Mochly-Rosen, manuscript in preparation.

(^4)
B. L. Smith and D. Mochly-Rosen, unpublished result.


ACKNOWLEDGEMENTS

We thank Dr. Adrienne Gordon for helpful discussions and Drs. Bernard Weinstein and Rafael Nesher for their generous gifts.


REFERENCES

  1. Nishizuka, Y. (1988) Nature 334,661-665 [CrossRef][Medline] [Order article via Infotrieve]
  2. Wolf, M., and Sahyoun, N. (1986) J. Biol. Chem. 261,13327-13332 [Abstract/Free Full Text]
  3. Zalewski, P. D., Forbes, I. J., Valente, L., Apostolous, S., and Hurst, N. P. (1988) Biochem. Pharmacol. 37,1415-1417 [Medline] [Order article via Infotrieve]
  4. Halsey, D. L., Girard, P. R., Kuo, J. F., and Blackshear, P. J. (1987) J. Biol. Chem. 262,2234-2243 [Abstract/Free Full Text]
  5. Chen, Z. Z., McGuire, J. C., Leach, K. L., and Cambier, J. C. (1987) J. Immunol. 138,2345-2352 [Abstract/Free Full Text]
  6. Masmoudi, A., Labourdette, G., Mersel, M., Huang, F. L., Huang, K.-P., Vincendon, G., and Malviya, A. N. (1989) J. Biol. Chem. 264,1172-1179 [Abstract/Free Full Text]
  7. Mochly-Rosen, D., Henrich, C. J., Cheever, L., Khaner, H., and Simpson, P. C. (1990) Mol. Biol. Cell 1,693-706
  8. Smith, B. L., and Mochly-Rosen, D. (1992) Biochem. Biophys. Res. Commun. 188,1235-1240 [Medline] [Order article via Infotrieve]
  9. Ron, D., and Mochly-Rosen, D. (1994) J. Biol. Chem. 269,21395-21398 [Abstract/Free Full Text]
  10. Parker, P. J., Kour, G., Marais, R. M., Mitchell, F., Pears, C., Schaap, D., Stabel, S., and Webster, C. (1989) Mol. Cell. Endocrinol. 65,1-11 [CrossRef][Medline] [Order article via Infotrieve]
  11. Burns, D. J., and Bell, R. M. (1991) J. Biol. Chem. 266,18330-18338 [Abstract/Free Full Text]
  12. Ono, Y., Fujii, T., Igarashi, K., Kuno, T., Tanaka, C., Kikkawa, U., and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,4868-4871 [Abstract]
  13. Quest, A. F. G., Bardes, E. S. G., and Bell, R. M. (1994) J. Biol. Chem. 269,2961-2970 [Abstract/Free Full Text]
  14. Kikkawa, U., Kishimoto, A., and Nishizuka, Y. (1989) Annu. Rev. Biochem. 58,31-44 [CrossRef][Medline] [Order article via Infotrieve]
  15. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., and Nishizuka, Y. (1988) J. Biol. Chem. 263,6927-6932 [Abstract/Free Full Text]
  16. Ohno, S., Akita, Y., Konno, Y., Imajoh, S., and Suzuki, K. (1988) Cell 53,731-741 [Medline] [Order article via Infotrieve]
  17. Neher, E., and Penner, R. (1994) Nature 372,316-317 [CrossRef][Medline] [Order article via Infotrieve]
  18. Perin, M. S., Fried, V. A., Mignery, G. A., Jahn, R., and Sudhof, T. C. (1990) Nature 345,260-263 [CrossRef][Medline] [Order article via Infotrieve]
  19. Mosior, M., and McLaughlin, S. (1991) Biophys. J. 60,149-159 [Abstract]
  20. Luo, J.-H., Kahn, S., O'Driscoll, K., and Weinstein, I. B. (1993) J. Biol. Chem. 268,3715-3719 [Abstract/Free Full Text]
  21. Clark, J. D., Lin, L.-L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., and Knopf, J. L. (1991) Cell 65,1043-1051 [Medline] [Order article via Infotrieve]
  22. Gopalakrishna, R., Barsky, S. H., Thomas, T. P., and Anderson, W. B. (1986) J. Biol. Chem. 261,16438-16445 [Abstract/Free Full Text]
  23. Wolf, M., and Baggiolini, M. (1990) Biochem. J. 269,723-728 [Medline] [Order article via Infotrieve]
  24. Mochly-Rosen, D., Khaner, H., and Lopez, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,3997-4000 [Abstract]
  25. Ron, D., Chen, C.-H., Caldwell, J., Jamieson, L., Orr, E., and Mochly-Rosen, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,839-843 [Abstract]
  26. Jaken, S., and Jones, W. A. (1992) in Protein Kinase C, Current Concepts and Future Perspectives (Lester, D. S., Epand, R. M., eds) pp. 237-273, Ellis Horwood, Ltd., W. Sussex, United Kingdom
  27. Hyatt, S. L., Liao, L., Chapline, C., and Jaken, S. (1994) Biochemistry 33,1223-1228 [Medline] [Order article via Infotrieve]
  28. Chapline, C., Ramsay, K., Klauck, T., and Jaken, S. (1993) J. Biol. Chem. 268,6858-6861 [Abstract/Free Full Text]
  29. Mochly-Rosen, D., Miller, K. G., Scheller, R. H., Khaner, H., Lopez, J., and Smith, B. L. (1992) Biochemistry 31,8120-8124 [Medline] [Order article via Infotrieve]
  30. Disatnik, M.-H., Hernandez-Stomayor, S., Jones, G., Carpenter, G., and Mochly-Rosen, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,559-563 [Abstract]
  31. Mochly-Rosen, D., and Koshland, D. E., Jr. (1987) J. Biol. Chem. 262,2291-2297 [Abstract/Free Full Text]
  32. Disatnik, M.-H., Buraggi, G., and Mochly-Rosen, D. (1994) Exp. Cell Res. 210,287-297 [CrossRef][Medline] [Order article via Infotrieve]
  33. Lohse, M. J., Lefkowitz, R. J., Caron, M. G., and Benovic, J. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,3011-3015 [Abstract]
  34. Liu, S.-H., Chu, J. C. J., and Ng, S.-Y. (1993) Nucleic Acids Res. 21,4005-4010 [Abstract]
  35. Padfield, P. J., Balch, W. E., and Jamieson, J. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,1656-1660 [Abstract]
  36. Jacob, M. C., Favre, M., and J-C, B. (1991) Cytometry 12,550-558 [Medline] [Order article via Infotrieve]
  37. Yanai, S., Sugiyama, Y., Iga, T., Fuwa, T., and Hanano, M. (1991) Pharm. Res. 8,557-562 [Medline] [Order article via Infotrieve]
  38. Erusalimsky, J. D., Brooks, S. F., Herget, T., Morris, C., and Rozengurt, E. (1991) J. Biol. Chem. 266,7073-7080 [Abstract/Free Full Text]
  39. Disatnik, M.-H., Winnier, A. R., Mochly-Rosen, D., and Arteaga, C. L. (1994) Cell Growth Diff. 5,873-880 [Abstract]
  40. Liao, L., Hyatt, S. L., Chapline, C., and Jaken, S. (1994) Biochemistry 33,1229-1233 [Medline] [Order article via Infotrieve]
  41. James, G., and Olson, E. N. (1992) J. Cell Biol. 116,863-874 [Abstract]
  42. Staudinger, J., Zhou, J., Burgess, R., Elledge, S. J., and Olson, E. N. (1995) J. Cell Biol. 128,263-271 [Abstract]
  43. Lehel, C., Olah, Z., Jakab, G., and Anderson, W. B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,1406-1410 [Abstract]
  44. Nalefski, E. A., Sultzman, L. A., Martin, D. M., Kriz, R. W., Towler, P. S., Knopf, J. L., and Clark, J. D. (1994) J. Biol. Chem. 269,18239-18249 [Abstract/Free Full Text]
  45. Gawler, D., Zhang, L.-J., Reedijk, M., Tung, P., and Moran, M. (1995) Oncogene 10,817-825 [Medline] [Order article via Infotrieve]
  46. Brose, N., Petrenko, A. G., Sudhof, T. C., and Jahn, R. (1992) Science 256,1021-1025 [Medline] [Order article via Infotrieve]
  47. Bommert, K., Charlton, M. P., DeBello, W. M., Chin, G. J., Betz, H., and Augustine, G. J. (1993) Nature 363,163-165 [CrossRef][Medline] [Order article via Infotrieve]
  48. Smith, L. D. (1989) Development 107,685-699 [Medline] [Order article via Infotrieve]
  49. Kishimoto, A., Kajikawa, N., Shiota, M., and Nishizuka, Y. (1983) 258,1156-1164
  50. Ford-Hutchinson, A. W. (1991) Trends Pharmacol. Sci. 12,68-70 [CrossRef][Medline] [Order article via Infotrieve]
  51. Mochly-Rosen, D., Khaner, H., Lopez, J., and Smith, B. L. (1991) J. Biol. Chem. 266,14866-14868 [Abstract/Free Full Text]
  52. Sutton, R. B., Davletov, B. A., Berghuis, A. M., Sudhof, T. C., and Sprang, S. R. (1995) Cell 80,929-938 [Medline] [Order article via Infotrieve]
  53. Nassar, N., Horn, G., Herrmann, C., Scherer, A., McCormick, F., and Wittinghofer, A. (1995) Nature 375,554-560 [CrossRef][Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.